-
Oral anticoagulant therapy in older adults Thromb. Res. (IF 7.5) Pub Date : 2024-04-14 J. Stuby, M. Haschke, T. Tritschler, D. Aujesky
Patients aged ≥65 years not only account for the majority of patients with atrial fibrillation (AF) and venous thromboembolism (VTE), they are also at a higher risk of morbidity, mortality, and undertreatment than younger patients. Several age-related physiological changes with effects on drug pharmacokinetics/−dynamics and blood vessel fragility as well as the higher prevalence of geriatric conditions
-
In-depth structure-function profiling of the complex formation between clotting factor VIII and heme Thromb. Res. (IF 7.5) Pub Date : 2024-04-13 Marie-T. Hopp, Deniz Ugurlar, Behnaz Pezeshkpoor, Arijit Biswas, Anuradha Ramoji, Ute Neugebauer, Johannes Oldenburg, Diana Imhof
-
Clinical and economic burden of immune tolerance induction in entire patients with hemophilia A: Insights from a real-world Korean setting Thromb. Res. (IF 7.5) Pub Date : 2024-04-13 Ah-Young Kim, Hee Jo Baek, Sukhyang Lee, Eunjung Choo, Young Shil Park, Hankil Lee
The most notable challenge facing hemophilia A treatment is the development of inhibitors against factor VIII, resulting in increased clinical and socioeconomic burdens due to the need for expensive bypassing agents (BPAs). Although immune tolerance induction (ITI) is currently the primary approach for inhibiting and reducing the inhibitors, the lengthy duration of ITI necessitates the continued use
-
Acute phase determinant of post-thrombotic syndrome: A review of the literature Thromb. Res. (IF 7.5) Pub Date : 2024-04-12 Lina Khider, Benjamin Planquette, David M. Smadja, Olivier Sanchez, Carla Rial, Guillaume Goudot, Emmanuel Messas, Tristan Mirault, Nicolas Gendron
Post-thrombotic syndrome (PTS) is the main long-term complication of deep vein thrombosis (DVT). Several therapies are being evaluated to prevent or to treat PTS. Identifying the patients most likely to benefit from these therapies presents a significant challenge. The objective of this review was to identify risk factors for PTS during the acute phase of DVT. We searched the PubMed and Cochrane databases
-
Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants? Thromb. Res. (IF 7.5) Pub Date : 2024-04-10 Nicolas Gendron, Paul Billoir, Virginie Siguret, Véronique Le Cam-Duchez, Valérie Proulle, Laurent Macchi, Elodie Boissier, Christine Mouton, Emmanuel De Maistre, Isabelle Gouin-Thibault, Georges Jourdi, French Society on Thrombosis and Haemostasis
-
Apixaban for the treatment of acute splanchnic vein thrombosis: A pilot study Thromb. Res. (IF 7.5) Pub Date : 2024-04-04 Sang-A Kim, Gwang Hyeon Choi, Ji Yun Lee, Eun Sun Jang, Jeong-Ok Lee, Jin-Wook Kim, Sook-Hyang Jeong, Soo-Mee Bang
-
Association between perioperative red blood cell transfusions and postoperative venous thromboembolism: A systematic review and meta-analysis Thromb. Res. (IF 7.5) Pub Date : 2024-04-03 Mengyan Mo, Zerong Lian, Yongyan Xiang, Xiaogang Du, Hua Liu, Jie Sun, Rui Wang
Whether perioperative red blood cell transfusions increases the risk of postoperative venous thromboembolism is controversial and uncertain.We aims to explore the relationship between perioperative red blood cell transfusions and the risk of postoperative venous thromboembolism by conducting a meta-analysis. To conduct a meta-analysis to systematically evaluate the relationship between perioperative
-
The emicizumab-bridged ternary complex with activated factor IX and factor X evaluated by fluorescence resonance energy transfer Thromb. Res. (IF 7.5) Pub Date : 2024-04-01 Akihisa Oda, Masahiro Takeyama, Takehisa Kitazawa, Keiji Nogami
-
Immature platelets and platelet reactivity in patients with acute ST-segment Elevation Myocardial Infarction using whole blood flow cytometry with SYTO-13 staining Thromb. Res. (IF 7.5) Pub Date : 2024-04-01 Oliver Buchhave Pedersen, Anne-Mette Hvas, Peter H. Nissen, Leonardo Pasalic, Steen Dalby Kristensen, Erik Lerkevang Grove
-
Acute pulmonary embolism in cancer patients admitted to intensive care unit: Impact of anticoagulant treatment on 90-day mortality and risk factors, results of a multicentre retrospective study Thromb. Res. (IF 7.5) Pub Date : 2024-03-31 Djamel Mokart, Edouard Serre, Fabrice Bruneel, Achille Kouatchet, Virginie Lemiale, Laurent Chow-Chine, Marion Faucher, Antoine Sannini, Sandrine Valade, Magali Bisbal, Frederic Gonzalez, Luca Servan, Michaël Darmon, Elie Azoulay
Acute pulmonary embolism (PE) is a life-threatening situation in cancer patients. In this situation, anticoagulant therapy is complex to administer due to the risk of bleeding. Only few studies have been conducted when these patients are admitted to the intensive care unit (ICU). The aim of this study was to assess the association between anticoagulation strategies as well as other factors with 90-day
-
Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-03-25 Antonios Douros, Ying Cui, Robert W. Platt, Kristian B. Filion, Giada Sebastiani, Christel Renoux
The effects of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (NVAF) and liver disease remain poorly understood. Our multinational cohort study assessed the effectiveness and safety of DOACs in this high-risk population. We assembled two population-based cohorts in United Kingdom and in Québec of NVAF patients with liver disease initiating DOACs or vitamin K antagonists
-
Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro Thromb. Res. (IF 7.5) Pub Date : 2024-03-22 Koji Yada, Natsume Fujitate, Kenichi Ogiwara, Tetsuhiro Soeda, Takehisa Kitazawa, Keiji Nogami
The hemostatic effect of recombinant (r) factor (F)VIIa after repetitive intermittent administration may be attenuated in patients with hemophilia A (PwHA) with inhibitors (PwHAwI) creating a clinically unresponsive status, although mechanism(s) remain to be clarified. In patients receiving prophylaxis treatment with emicizumab, concomitant rFVIIa is sometimes utilized in multiple doses for surgical
-
Syk inhibition suppresses NLRP3 inflammasome activation in platelets from sickle cell mice leading to decreased platelet secretion, aggregation, spreading, and in vitro thrombus formation Thromb. Res. (IF 7.5) Pub Date : 2024-03-22 Sebastian Vogel, Sayuri Kamimura, Meghann L. Smith, Luis E.F. Almeida, Xizhong Cui, Christian A. Combs, Zenaide M.N. Quezado
-
Venous thromboembolism (VTE) developing after ankle sprain. Comparison with VTE after knee arthroplasty Thromb. Res. (IF 7.5) Pub Date : 2024-03-21 Javier Gutiérrez-Guisado, Alejo Erice Calvo-Sotelo, Luis Hernández-Blasco, Ángeles Fidalgo, Covadonga Gómez-Cuervo, Antonio López-Ruiz, Jesús Aibar, Peter Verhamme, José Meireles, Manuel Monreal
Venous thromboembolism (VTE) is a critical complication after non-major trauma or surgery. While the risk and severity of VTE following major orthopedic surgery is well-documented, there is significant knowledge gap regarding, non-major trauma such as ankle sprains. We analyzed data from the RIETE registry to assess the clinical characteristics, VTE prophylaxis usage, and outcomes in patients with
-
Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation Thromb. Res. (IF 7.5) Pub Date : 2024-03-21 Yuto Nakajima, Kenichi Ogiwara, Keito Inaba, Takehisa Kitazawa, Keiji Nogami
-
Mucin 1 and venous thrombosis in tumor-bearing mice and patients with cancer Thromb. Res. (IF 7.5) Pub Date : 2024-03-21 Tomohiro Kawano, Cornelia Englisch, Yohei Hisada, David Paul, Sierra Archibald, Steven Grover, Ingrid Pabinger, Cihan Ay, Nigel Mackman
Mucins released from epithelial tumors have been proposed to play a role in cancer-associated thrombosis. Mucin1 (MUC1) is a transmembrane mucin that is overexpressed in a variety of human malignancies, including breast and pancreatic cancer. We analyzed the association of MUC1 and venous thrombosis in a mouse tumor model and in patients with cancer. We used a human pancreatic cancer cell line HPAF-II
-
Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation Thromb. Res. (IF 7.5) Pub Date : 2024-03-20 Brianna R. Bakow, Lisa Yanek, Mark A. Crowther, Shruti Chaturvedi
Thrombotic antiphospholipid syndrome (TAPS) is characterized by thrombosis and persistently positive tests for antiphospholipid antibodies or lupus anticoagulant (LAC). Triple-positive APS has the highest risk of recurrent thrombosis, but no studies have focused on recurrent thrombosis in patients with single-positive TAPS. We conducted a retrospective cohort study of patients with single-positive
-
Sepsis induces heterogeneous transcription of coagulation- and inflammation-associated genes in renal microvasculature Thromb. Res. (IF 7.5) Pub Date : 2024-03-18 Matthijs Luxen, Peter J. Zwiers, Rianne M. Jongman, Jill Moser, Marianne Pultar, Susanna Skalicky, Andreas B. Diendorfer, Matthias Hackl, Matijs van Meurs, Grietje Molema
-
Comprehensive investigation of platelet function in patients with cirrhosis Thromb. Res. (IF 7.5) Pub Date : 2024-03-16 Anna Lecchi, Giulia Tosetti, Claudia Ghali, Silvia La Marca, Marigrazia Clerici, Lidia Padovan, Eti A. Femia, Massimo Primignani, Vincenzo La Mura, Pietro Lampertico, Flora Peyvandi, Armando Tripodi
Cirrhosis presents with thrombocytopenia and possibly thrombocytopathy. Previous studies exploring platelet function gave conflicting results and most controversies are explained by the variety of methods employed for investigation. We sought to assess the overall platelet function in cirrhosis.
-
The incidence of venous thromboembolism after curative colon cancer surgery within an enhanced recovery after surgery programme Thromb. Res. (IF 7.5) Pub Date : 2024-03-15 Niklas Nygaard Baastrup, Astrid Kerstine Buch, Anders Kierkegaard Gundestrup, Anna Sofie Friis Olsen, Jakob Kleif, Issam Al-Najami, Ulrik Deding, Claus Anders Bertelsen, COMES II - Copenhagen cOmplete Mesocolic Excision Study II study group, the Danish Colorectal Cancer Group
Based on three randomised controlled trials performed more than a decade ago, several national guidelines recommend prolonged venous thromboprophylaxis for 28 days following elective surgery for colon cancer. None of these studies were conducted within enhanced recovery after surgery setting. Newer studies indicate that prolonged prophylaxis might not be necessary with enhanced recovery after surgery
-
Does morphine attenuate the Inhibition of Platelet Aggregation for both oral and parenteral P2Y12 inhibitors? Thromb. Res. (IF 7.5) Pub Date : 2024-03-15 Antonio Landi, Giuseppe Gargiulo, Giovanni Esposito, Gianluca Campo, Simone Biscaglia, Dik Heg, Marco Valgimigli
-
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients Thromb. Res. (IF 7.5) Pub Date : 2024-03-15 H. Lévesque, J.F. Viallard, E. Houivet, B. Bonnotte, S. Voisin, V. Le Cam-Duchez, F. Maillot, M. Lambert, E. Liozon, B. Hervier, O. Fain, B. Guillet, J. Schmidt, L.E. Luca, M. Ebbo, N. Ferreira-Maldent, A. Babuty, L. Sailler, P. Duffau, V. Barbay, S. Audia, J. Benichou, J. Graveleau, Y. Benhamou, CREHA Study investigators on behalf the scientific committee of the “Société Nationale Française de Médecine
Acquired hemophilia A (AHA) is a rare autoimmune disorder due to autoantibodies against Factor VIII, with a high mortality risk. Treatments aim to control bleeding and eradicate antibodies by immunosuppression. International recommendations rely on registers and international expert panels. CREHA, an open-label randomized trial, compared the efficacy and safety of cyclophosphamide and rituximab in
-
Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban Thromb. Res. (IF 7.5) Pub Date : 2024-03-15 Cindy Pereira Portela, Guido Stirnimann, Dino Kröll, Alessandro Aliotta, Lucas Veuthey, Maxime G. Zermatten, Lorenzo Alberio, Debora Bertaggia Calderara
-
Prognostic gene landscapes and therapeutic insights in sepsis-induced coagulopathy Thromb. Res. (IF 7.5) Pub Date : 2024-03-12 Xiaoli Ran, Jun Zhang, Yinyu Wu, Yunxia Du, Daiqin Bao, Haoyu Pei, Yue Zhang, Xiaoqiong Zhou, Rui Li, Xu Tang, Han She, Qingxiang Mao
-
Aiming for precision: CYP2C19 gene polymorphism and clopidogrel resistance in patients with peripheral artery disease Thromb. Res. (IF 7.5) Pub Date : 2024-03-08 Sina Rashedi, Parham Sadeghipour, Junyang Lou
-
The role of coagulation factors VIII, IX and XI in the prediction and mediation of recurrent thrombotic events in children with non-central venous catheter deep vein thrombosis Thromb. Res. (IF 7.5) Pub Date : 2024-03-07 Alessandra Bosch, Kirsten Brunsvig Jarvis, Leonardo R. Brandão, Yushu Zou, Jennifer Vincelli, Nour Amiri, Laura Avila
The role of elevated coagulation factors VIII (FVIII), FIX, FXI for the prediction of recurrent thrombotic events in children after an index non-central venous catheter (non-CVC) related deep vein thrombosis (DVT) remains unclear. This study investigates the predictive role of FVIII, FIX, and FXI for recurrent thrombosis in children with index non-CVC DVTs, and the mediation effect of FVIII on chronic
-
Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure? Thromb. Res. (IF 7.5) Pub Date : 2024-03-07 Julie Vassart, Marie Didembourg, Laure Morimont, Clotilde Brisbois, Laurent Jamart, Aurélien Lebreton, François Mullier, Nathalie Donis, Julien Favresse, Jean-Michel Dogné, Jonathan Douxfils
-
Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-03-06 Joon Young Hur, Nayeon Choi, Jung Hye Choi, Jiyeong Kim, Young-Woong Won
There are few large-scale, population-based studies detailing the risks of thrombosis, hemorrhage, leukemic transformation in patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). We performed a nationwide longitudinal cohort study using the Korean National Health Insurance System (NHIS) database. MPN patients
-
Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease Thromb. Res. (IF 7.5) Pub Date : 2024-03-05 Jacobina Kristiansen, Erik L. Grove, Tórur Sjúrðarson, Magni Mohr, Steen D. Kristensen, Anne-Mette Hvas
Strenuous exercise may occasionally cause coronary thrombosis with myocardial infarction and sudden cardiac death. Patients with stable coronary artery disease (CAD) ( = 164) and healthy individuals ( = 25) performed strenuous exercise on a bicycle ergometer. Blood was drawn at baseline, immediately after exercise and 2 h later. Platelet aggregation was measured with Multiplate® Analyzer. Thrombin
-
Platelet factor 4 promotes deep venous thrombosis by regulating the formation of neutrophil extracellular traps Thromb. Res. (IF 7.5) Pub Date : 2024-03-05 Wenqiang Li, Decai Chi, Shuai Ju, Xinyi Zhao, Xiaoyan Li, Junjie Zhao, Huiqi Xie, Yao Li, Jiaqi Jin, Ge Mang, Zhihui Dong
The presence of neutrophil extracellular traps (NETs) in thrombotic diseases has been extensively studied. The exact mechanism of NET formation in deep venous thrombosis (DVT) has not been largely studied. This study is aimed to explore the role of NETs and their interaction with platelet factor 4 (PF4) in DVT. In plasma samples from 51 healthy volunteers and 52 DVT patients, NET markers and PF4 were
-
Impact of allele-selective silencing of von Willebrand factor in mice based on a single nucleotide allelic difference in von Willebrand factor Thromb. Res. (IF 7.5) Pub Date : 2024-03-05 Yvonne K. Jongejan, Noa A. Linthorst, Elisa Schrader Echeverri, Sebastiaan N.J. Laan, Richard J. Dirven, James E. Dahlman, Bart J.M. van Vlijmen, Cécile V. Denis, Jeroen C.J. Eikenboom
-
Fundamental considerations for designing endothelialized in vitro models of thrombosis Thromb. Res. (IF 7.5) Pub Date : 2024-03-05 Titus P. Lemmens, Vanessa Bröker, Minke Rijpkema, Christopher C.W. Hughes, Leon J. Schurgers, Judith M.E.M. Cosemans
Endothelialized models for cardiovascular disease have contributed greatly to our current understanding of the complex molecular mechanisms underlying thrombosis. To further elucidate these mechanisms, it is important to consider which fundamental aspects to incorporate into an model. In this review, we will focus on the design of in vitro endothelialized models of thrombosis. Expanding our understanding
-
Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study Thromb. Res. (IF 7.5) Pub Date : 2024-03-05 Oğuzhan Firat, Emre Kara, Ümit Yavuz Malkan, Kutay Demirkan, Ahmet Çağkan Inkaya
Tigecycline-associated hypofibrinogenemia has been reported as an important adverse effect in recent years, but controlled studies minimizing confounding factors are needed. The objective of our study was to assess changes in fibrinogen levels in patients for hospitalization, comparing two antibiotic episodes (tigecycline and other) within the same patients. The retrospective, self-controlled case
-
Effects of gender affirming hormone therapy with testosterone on coagulation and hematological parameters in transgender people assigned female at birth: A systematic review and meta-analysis Thromb. Res. (IF 7.5) Pub Date : 2024-03-04 Daniele Tienforti, Daniele Pastori, Arcangelo Barbonetti
Hormone replacement therapy is associated with an increased thromboembolic risk. The effects of testosterone (T) on coagulation markers in people assigned female at birth (AFAB) under gender affirming hormone therapy (GAHT) are not well described. Systematic review and meta-analysis on English-language articles retrieved from PubMed, Scopus and Cochrane Library up to April 2023 investigating T therapy
-
Impact of very low dose rivaroxaban in addition to dual antiplatelet therapy on endogenous fibrinolysis in acute coronary syndrome: The VaLiDate-R study Thromb. Res. (IF 7.5) Pub Date : 2024-03-03 Ying X. Gue, Vassilios Memtsas, Rahim Kanji, David M. Wellsted, Amanda Busby, Megan Smith, Enric Vilar, Alisdair Ryding, Deepa J. Arachchillage, Diana A. Gorog
Impaired endogenous fibrinolysis is adverse cardiovascular risk factor in acute coronary syndrome (ACS) patients. Addition of very low dose rivaroxaban (VLDR) to dual antiplatelet therapy (DAPT) reduces cardiovascular events but increases bleeding. We aimed to assess whether addition of VLDR to DAPT can enhance endogenous fibrinolysis. In a prospective, open-label trial, we assessed endogenous fibrinolysis
-
Effect of statin intake on FVIII levels and bleeding outcomes in hypercholesterolemic patients with hemophilia A Thromb. Res. (IF 7.5) Pub Date : 2024-03-02 Francesco Paciullo, Stefania Momi, Maria Elisa Mancuso, Cristina Santoro, Mariasanta Napolitano, Giancarlo Castaman, Ezio Zanon, Laura Contino, Raimondo De Cristofaro, Rita Carlotta Santoro, Paolo Gresele
-
Anticoagulation with argatroban using hemoclot™ targets is safe and effective in CARDS patients receiving venovenous extracorporeal membrane oxygenation: An exploratory bi-centric cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-03-02 Timo Mayerhöfer, Michael Joannidis, Andreas Peer, Fabian Perschinka, Dietmar Fries, Peter Mair, Lukas Gasteiger, Mirjam Bachler, Juliane Kilo, Harald Herkner, Michael Schwameis, Peter Schellongowski, Bernhard Nagler, Andrea Kornfehl, Thomas Staudinger, Nina Buchtele
-
Fragility and long-term clinical outcomes in patients with venous thromboembolism receiving direct oral anticoagulants: From the COMMAND VTE REGISTRY-2 Thromb. Res. (IF 7.5) Pub Date : 2024-02-29 Yoshito Ogihara, Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, Kazuhisa Kaneda, Yuji Nishimoto, Nobutaka Ikeda, Yohei Kobayashi, Satoshi Ikeda, Kitae Kim, Moriaki Inoko, Toru Takase, Shuhei Tsuji, Maki Oi, Takuma Takada, Kazunori Otsui, Jiro Sakamoto, Takeshi Inoue, Shunsuke Usami, Po-Min Chen, Kiyonori Togi, Norimichi Koitabashi, Seiichi Hiramori, Kosuke Doi, Hiroshi Mabuchi, Yoshiaki Tsuyuki,
There is limited data on the safety of direct oral anticoagulants (DOACs) in fragile patients with venous thromboembolism (VTE). We used the COMMAND VTE Registry-2 enrolling patients with acute symptomatic VTE. The study population consisted of 3928 patients receiving DOACs, who were divided into fragile (2136 patients) and non-fragile groups (1792 patients). Fragility was defined as patients of age ≥ 75 years
-
Comparison of inferior vena cava filter use and outcomes between cancer and non-cancer patients in a tertiary hospital Thromb. Res. (IF 7.5) Pub Date : 2024-02-28 Néstor López, Carles Zamora-Martinez, Marc Montoya-Rodes, Cristina Gabara, María Ortiz, Jesús Aibar
While accepted indications for the use of inferior vena cava filter (IVCF) in patients with a venous thromboembolism (VTE) have remained stable, their use continues to be frequent. Retrieval rates are still low, being particularly notable in the population with cancer. This study aims to review the rate of adherence to guidelines recommendation and to compare retrieval rates and complications in both
-
Enoxaparin is safe for the treatment of venous thromboembolisms in patients with renal dysfunction: A retrospective cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-02-27 Connor Flynn, Julie Baldassarra, Arzo Hamidi
-
Complications associated to midline- and long peripheral catheters in adults. Systematic review of literature and proposal for a standardized model for data collection Thromb. Res. (IF 7.5) Pub Date : 2024-02-26 Adam Fabiani, Nicola Aversana, Marilena Santoro, Gianfranco Sanson
Long peripheral catheters (LPCs) and midline catheters (MCs) are indiscriminately labelled with different names, leading to misclassifications both in primary and secondary studies. The available studies used different methods to report the incidence of catheter-related complications, affecting the possibility of properly comparing the catheter outcomes. The aim of this review was to explore the complications
-
Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE Registry Thromb. Res. (IF 7.5) Pub Date : 2024-02-24 Carmine Siniscalchi, Behnood Bikdeli, David Jiménez, José María Suriñach, Pablo Demelo-Rodríguez, Farès Moustafa, Aída Gil-Díaz, Alberto García-Ortega, Hanh My Bui, Manuel Monreal, RIETE Investigators
The association between statin use and mortality in patients with deep vein thrombosis (DVT) has not been rigorously evaluated. We used the data in the RIETE registry to examine the association between statin use and mortality at 3 months. We used mixed effects survival models accounting for clinical covariates and clustering of patients in enrolling centers. From January 2009 through April 2022, there
-
Considerations for instituting pediatric pulmonary embolism response teams: A tool kit Thromb. Res. (IF 7.5) Pub Date : 2024-02-22 Madhvi Rajpurkar, Rachel P. Rosovsky, Suzan Williams, Anthony K.C. Chan, C. Heleen van Ommen, E. Vincent S. Faustino, Melissa White, Mihir Parikh, Nongnuch Sirachainan, Tina Biss, Neil A. Goldenberg
The incidence of pediatric pulmonary embolism (PE) has increased by 200 % in the last decade, but at a single center, it is still infrequent. Given the unique epidemiologic features of pediatric PE, diagnosis is often delayed, and the management is empiric, based on individual physician experience or preference. Thus, there is a strong need for center-specific uniform management of pediatric PE patients
-
Patterns of atrial fibrillation anticoagulation with rivaroxaban — 7-year follow-up from the Dresden NOAC registry Thromb. Res. (IF 7.5) Pub Date : 2024-02-19 Luise Tittl, Sandra Marten, Christiane Naue, Jan Beyer-Westendorf
Data on long-term effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) are scarce and not available from randomized clinical trials. We used data from the prospective, non-interventional to evaluate rates of stroke/transient ischaemic attack (TIA)/systemic embolism (SE) and ISTH major bleeding, in general and changes of event patterns over time. Between 1st October
-
Diagnostic strategies in postpartum individuals with suspected venous thromboembolism: A scoping review Thromb. Res. (IF 7.5) Pub Date : 2024-02-19 Gurjeet Bhangu, Alistair Murray, Areeb Qayyum, Natasha Goumeniouk, Steve Goodacre, Beverley J. Hunt, Omar Touhami, Jodie Tester, Megan Rees, Gary Hammerschlag, Diane Pascoe, Paul E. Ronksley, James A. King, Hyun Choi, Shaunagh McDermott, Gregoire Le Gal, Leslie Skeith
The risk of venous thromboembolism (VTE) is increased postpartum and contributes to important morbidity and mortality. While there have been advances in evaluating diagnostic algorithms for suspected VTE during pregnancy, there is limited data for postpartum individuals. We conducted a scoping review to describe and evaluate diagnostic strategies used to investigate suspected VTE in postpartum individuals
-
DOACs: A perfect fit for patients with bariatric surgery? Thromb. Res. (IF 7.5) Pub Date : 2024-02-18 Nicolas Gendron, Azita H. Talasaz
-
The effects of CYP2C19 genotype polymorphism and clopidogrel resistance on ischemic event occurrence in patients with peripheral arterial disease undergoing revascularization: A prospective cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-02-17 Yongkang Zhang, Qingzhi Ran, Kangli Yin, Yinkai Wang, Jiarui Liu, Yuan Zong, Yuzhen Wang, Yemin Cao
-
Standardized direct oral anticoagulants prescription for treatment of acute venous thromboembolism in the emergency department: A quality improvement initiative Thromb. Res. (IF 7.5) Pub Date : 2024-02-16 C. Simard, L. Poirier-Blanchette, A. Rizzolo, T. Cafaro, R. Kerzner, H. Mantzanis, M. Koolian, Canadian Venous Thromboembolism Research Network (CanVECTOR)
-
Multitarget strategy of GATA3 and high-grade serous ovarian carcinoma: Where are we now? Thromb. Res. (IF 7.5) Pub Date : 2024-02-16 Mohnad Abdalla, Amr Ahmed El-Arabey, Zhongtao Gai
-
Pregnancy outcomes in Chinese women with mechanical heart valves receiving warfarin treatment throughout pregnancy: 14-year experience Thromb. Res. (IF 7.5) Pub Date : 2024-02-16 Tianyu Li, Lei Chen, Mei Peng, Guobao Song, Chunyan Wang, Qiyun Peng, Shenglan Tan
-
Altered fibrin clot properties are associated with the progression of chronic kidney disease in atrial fibrillation Thromb. Res. (IF 7.5) Pub Date : 2024-02-16 Zbigniew Heleniak, Paweł T. Matusik, Anetta Undas
Formation of denser and resistant to lysis fibrin clot networks has been shown in chronic kidney disease (CKD) and atrial fibrillation (AF). We investigated whether such prothrombotic fibrin clot properties are associated with faster progression of CKD in AF patients. We recruited 265 AF patients (men 49.1 %, median age of 64.0 years, median estimated glomerular filtration rate [eGFR] of 77.0 ml/min/1
-
The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia Thromb. Res. (IF 7.5) Pub Date : 2024-02-16 Giovangiacinto Paterno, Raffaele Palmieri, Cristiano Tesei, Andrea Nunzi, Giorgia Ranucci, Flavia Mallegni, Federico Moretti, Elisa Meddi, Ilaria Tiravanti, Massimiliano Marinoni, Camilla Page, Solaria Fagiolo, Elisa Buzzatti, Roberto Secchi, Carmelo Gurnari, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe
Coagulation disorders frequently complicate the clinical course of acute myeloid leukemia (AML) patients. This study examined the frequency and prognostic significance, with regards of early mortality, of the presence of overt disseminated intravascular coagulation (DIC) at AML diagnosis and its correlation with clinical and biological characteristics.
-
Current and potentially novel antithrombotic treatment in acute ischemic stroke Thromb. Res. (IF 7.5) Pub Date : 2024-02-15 Angelique Ceulemans, Henri M.H. Spronk, Hugo ten Cate, Wim H. van Zwam, Robert J. van Oostenbrugge, Magdolna Nagy
Acute ischemic stroke (AIS) is the most common type of stroke and requires immediate reperfusion. Current acute reperfusion therapies comprise the administration of intravenous thrombolysis and/or endovascular thrombectomy. Although these acute reperfusion therapies are increasingly successful, optimized secondary antithrombotic treatment remains warranted, specifically to reduce the risk of major
-
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-02-15 Li Bao, Li-juan Fang, Meng-yu Xiao, Min-qiu Lu, Bin Chu, Lei Shi, Shan Gao, Qiu-qing Xiang, Yu-tong Wang, Xi Liu, Yue-hua Ding, Zhao Xin, Yuan Chen, Meng-zhen Wang, Wei-kai Hu, Cheng-yu Guo, Ling-yun Chen, Kai Sun
Multiple myeloma (MM) significantly increases the risk of venous thromboembolism (VTE) within 6 months of treatment initiation. The IMPEDE VTE score is a VTE risk prediction model which is recently incorporated into the National Comprehensive Cancer Network (NCCN) guidelines, but it lacks validation among Asians, including Chinese MM patients. We performed a retrospective chart review of 405 Chinese
-
Letter in response to a recent article by Zhang et al.[ ] Thromb. Res. (IF 7.5) Pub Date : 2024-02-15 Martina Perego, Maria Calloni, Alba Taino, Chiara Cogliati, Antonio Gidaro
-
Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-02-13 Renate C.A.E. van Uden, Tessa C.C. Jaspers, Karina Meijer, Karlijn J. van Stralen, Barbara Maat, Nakisa Khorsand, Hein A.W. van Onzenoort, Eleonora L. Swart, Harmen J. Huls, Ron A.A. Mathôt, Michaël V. Lukens, Patricia M.L.A. van den Bemt, Matthijs L. Becker
-
Anticoagulation of pediatric patients with venous thromboembolism in 2023 Thromb. Res. (IF 7.5) Pub Date : 2024-02-10 C. Heleen van Ommen, Saskia E. Luijnenburg
-
Recapitulating the immune system of hemophilia A patients with inhibitors using immunodeficient mice Thromb. Res. (IF 7.5) Pub Date : 2024-02-08 Sheng-Chieh Chou, Ching-Tzu Yen, Yung-Li Yang, Shu-Huey Chen, Jiaan-Der Wang, Meng-Ni Fan, Li-Fu Chen, I-Shing Yu, Dong-Yan Tsai, Kuo-I Lin, Mi-Hua Tao, Jui-ching Wu, Shu-Wha Lin
Treating hemophilia A patients who develop inhibitors remains a clinical challenge. A mouse model of hemophilia A can be used to test the efficacy of strategies for inhibitor suppression, but the differences in the immune systems of mice and humans limit its utility. To address this shortcoming, we established a humanized NOD/SCID-IL2rγ hemophilia A (hu-NSG-HA) mouse model with a severely deficient
-
White blood cell subtypes and neutrophil extracellular traps as biomarkers for stroke etiology Thromb. Res. (IF 7.5) Pub Date : 2024-02-06 Kousar Ahmadi, Ehsan Alimohammadi
-
Frequency of the p.Thr241Asn mutation in Chinese patients with congenital factor VII deficiency Thromb. Res. (IF 7.5) Pub Date : 2024-02-06 Puhui Zhou, Yan Peng, Qingcheng Li, Qingshui Huang, Yunyuan Kong